Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|March 14, 2024
Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescentsOliver L Sampson, Cecilia Jay, Emily Adland, et al.
Nature Communications|May 16, 2024
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in GuineaJoseph Akoi Boré, Joseph W S Timothy, Tom Tipton, et al.
Frontiers in Immunology|September 15, 2023
Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family membersCecilia Jay, Emily Adland, Anna Csala, et al.
Clinical and Experimental Immunology|February 22, 2023
Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccinationSíle A Johnson, Eloise Phillips, Sandra Adele, et al.
Frontiers in Immunology|February 28, 2022
Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus MacaquesAndrew D White, Laura Sibley, Charlotte Sarfas, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Vaccine|July 13, 2021
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge modelKaren E Gooch, Trevor R F Smith, Francisco J Salguero, et al.
Mbio|September 1, 2023
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH studyIsabel Neale, Mohammad Ali, Barbara Kronsteiner, et al.
The Lancet. Microbe|May 4, 2024
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studySusan Jackson, Julia L Marshall, Andrew Mawer, et al.
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Pageof 5